
Angiogenesis
Subcategories of "Angiogenesis"
- BTK(167 products)
- Bcr-Abl(118 products)
- EGFR(581 products)
- FAK(72 products)
- FLT(86 products)
- Fibroblast Growth Factor Receptor (FGFR)(180 products)
- JAK(243 products)
- PDGFR(129 products)
- RAAS(89 products)
- Src(82 products)
- Syk(37 products)
- Thrombin(57 products)
- VDA(2 products)
- VEGFR(242 products)
Found 2382 products of "Angiogenesis"
Syk Inhibitor II
CAS:Syk inhibitor II, a cell-permeable, ATP-competitive, pyrimidine-carboxamide compound, selectively and reversibly inhibits Syk (IC50 = 41 nM).Formula:C14H15F3N6OPurity:97.63%Color and Shape:SolidMolecular weight:340.3Gefitinib-d6
CAS:Gefitinib-d6 is a deuterated compound of Gefitinib. Gefitinib has a CAS number of 184475-35-2. Gefitinib is an EGFR tyrosine kinase inhibitor and can inhibit Tyr1173, Tyr992, Tyr1173 and Tyr992 (IC50s: 37/37/26/57 nM).Formula:C22H18D6ClFN4O3Color and Shape:SolidMolecular weight:452.94(Rac)-SAR131675
CAS:(Rac)-SAR131675 is an effective and specific VEGFR-3 inhibitor, which inhibited VEGFR-3 tyrosine kinase activity and VEGFR-3 autophosphorylation in HEK cells.Formula:C18H22N4O4Purity:98.73% - 99.1%Color and Shape:SolidMolecular weight:358.39Naquotinib mesylate
CAS:Naquotinib mesylate (ASP8273 (mesylate)) is an orally available, mutant-selective and irreversible inhibitor of EGFR(iC50s of 8-33 nM and 230 nM for toward EGFRFormula:C31H46N8O6SPurity:98%Color and Shape:SolidMolecular weight:658.81Canertinib dihydrochloride
CAS:Canertinib dihydrochloride (PD-183805 dihydrochloride) is the hydrochloride salt of an orally bio-available quinazoline with potential antineoplastic andFormula:C24H27Cl3FN5O3Purity:99.13% - >99.99%Color and Shape:SolidMolecular weight:558.86PF-03814735
CAS:PF-03814735 is a novel, potent and reversible inhibitor of Aurora A/B with IC50of 0.8 nM/5 nM, is less potent to Flt3, FAK, TrkA, and minimally active to Met and FGFR1. Phase 1.Formula:C23H25F3N6O2Purity:98%Color and Shape:SolidMolecular weight:474.48Almonertinib hydrochloride
CAS:Almonertinib hydrochloride (HS-10296 hydrochloride) is a small molecule inhibitor of EGFR-activating mutations and T790M-resistant mutation.Formula:C30H36ClN7O2Purity:98.01% - 98.12%Color and Shape:SolidMolecular weight:562.1BIBF 1202
CAS:BIBF 1202 is a VEGFR2 kinase inhibitor (IC50 = 62 nM).Formula:C30H31N5O4Purity:98.04%Color and Shape:SolidMolecular weight:525.6Brivanib (alaninate)
CAS:Brivanib Alaninate (BMS-582664) is an alaninate salt of a vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor with potential antineoplastic effect.Formula:C22H24FN5O4Purity:99.46% - 99.66%Color and Shape:SolidMolecular weight:441.46BMS-690514
CAS:BMS-690514 is a potent and orally active inhibitor of EGFR and VEGFR. It has IC50s of 5, 20 and 60 nM for EGFR, HER 2 and HER 4, respectively.Formula:C19H24N6O2Purity:99.08%Color and Shape:SolidMolecular weight:368.43NVP-BSK805
CAS:NVP-BSK805 (BSK 805) is an ATP-competitive JAK2 inhibitor.Formula:C27H28F2N6OPurity:98%Color and Shape:SolidMolecular weight:490.55Methyl 6-[[[(2-Chloroethyl)amino]carbonyl]amino]-6-deoxy-Alpha-D-glucopyranoside
CAS:Controlled ProductFormula:C10H19ClN2O6Color and Shape:NeatMolecular weight:298.72Behenamide
CAS:Controlled ProductApplications Behenamide is a fatty acid amide as an angiogenic. The mechanism of angiogenic activity is unknown and this lipid does not promote proliferation of endothelial cells or induce inflammatory effects.
References Wakamatsu, K., et al.: Biochem. Biophysical Res. Comm., 168, 423 (1990),Formula:C22H45NOColor and Shape:White To Off-WhiteMolecular weight:339.6(5E)-5-(4-Hydroxybenzylidene)-1,3-thiazolidine-2,4-dione
CAS:Controlled ProductApplications 5-[(4-Hydroxyphenyl)methylene]-2,4-thiazolidinedione is a 5-Benzylidene-2,4-thiazolidenedione derivative designed as inhibitors of angiogenesis targeting VEGFR-2. Also, it is an intermediate used in the synthesis of MSDC 0602 (M755420), which is an analogue of thiazolidinediones, exhibits low affinity for binding and activation of peroxisome proliferator-activated receptor γ (PPARγ). Thiazolidinediones are effective insulin-sensitizing drugs for treating various metabolic and inflammatory diseases.
References Bhanushali, U., et al.: Bioorg. Chem., 67, 139-147 (2016); Chen, Z., et al.: J. Biol. Chem. 287, 23537 (2012); Fukunaga, T., et al.: J. Bone Miner. Res., 30, 508 (2015)Formula:C10H7NO3SColor and Shape:NeatMolecular weight:221.23Bafisontamab
CAS:Bafisontamab (EMB-01) is a bispecific antibody that targets EGFR and cMET, displaying antitumor activity [1].Color and Shape:LiquidTovetumab
CAS:Tovetumab (MEDI-575) is an anti-PDGFRα mAb inhibiting its signaling, in trials for glioblastoma and NSCLC.Purity:95%Color and Shape:LiquidMolecular weight:144.78 kDaIvonescimab
CAS:Ivonescimab (AK112) is a PD-1/VEGF bispecific antibody with cancer immunotherapy and anti-angiogenic effects, NSCLC).Purity:95% - >95.0% (SDS-PAGE); 98.99% (SEC-HPLC)Color and Shape:LiquidMolecular weight:201.12 kDaTarcocimab
CAS:Tarcocimab (OG1953) is a humanized IgG1 monoclonal antibody targeting VEGFA, researched for RVO and wet AMD.Color and Shape:LiquidImgatuzumab
CAS:Imgatuzumab (RG 7160) is a humanized anti-EGFR monoclonal antibody and immunomodulator for cancer research.
Color and Shape:LiquidMolecular weight:145.0 (kDa)Solrikitug
CAS:Solrikitug,Anti-CRLF2 humanized IgG1κ monoclonal antibody.Purity:95%Color and Shape:LiquidMolecular weight:~150 kDaEGFR T790M/L858R-IN-8
CAS:EGFRT790M/L858R-IN-8 (compound 9) is a potent inhibitor of EGFR, specifically targeting the EGFRT790M/L858R mutations with an IC50 of 56.8 μM. This compound does not show significant antiproliferative effects on cancer cell lines A549, A431, and NHI-H1975.Formula:C16H11BrN2O3Color and Shape:SolidMolecular weight:359.17Vanucizumab
CAS:Vanucizumab is a bispecific humanised monoclonal antibody that simultaneously inhibits the receptor interactions of VEGF-A and Angiopoietin-2 (Ang-2)Purity:95%Color and Shape:LiquidMolecular weight:146.89 kDaElgemtumab
CAS:Elgemtumab (LJM716) is a fully humanised monoclonal antibody targeting HER3/ERBB3, acting as an antagonist to block HER3/Akt phosphorylation antitumour.Purity:95%Color and Shape:LiquidMolecular weight:144.15 kDaZalutumumab
CAS:Zalutumumab is a high-affinity fully human monoclonal antibody ,the extracellular domain of the EGFR squamous cell carcinoma of the head and neck (SCCHN).Purity:95%Color and Shape:LiquidMolecular weight:146.63 kDaSerclutamab
CAS:Serclutamab, a humanized chimeric monoclonal antibody of the IgG1-κ isotype, selectively targets the epidermal growth factor receptor (EGFR).Purity:98%Color and Shape:LiquidAnti-Mouse VEGFR-2 Antibody (DC101)
Anti-Mouse VEGFR-2 Antibody (DC101) is a rat-derived monoclonal antibody against mouse VEGFR2/KDR/Flk-1, serving as a mouse analogue of ramucirumab.Purity:99%Color and Shape:LiquidMolecular weight:150 kDaBecotatug
CAS:Becotatug (JMT101) is a humanised monoclonal antibody targeting EGFR, antitumour when combined with Osimertinib for treating EGFR-mutated advanced NSCLC.Purity:95% - 99.1% (SDS-PAGE); 98.1% (SEC-HPLC)Color and Shape:LiquidMolecular weight:145.52 kDaIzalontamab
CAS:Izalontamab (SI-B001) is a bispecific EGFR/HER3 monoclonal antibody that binds to both EGFR×EGFR homodimers and EGFR×HER3 heterodimers.Purity:95%+ - 95.3% (SDS-PAGE); 99.2% (SEC-HPLC)Color and Shape:LiquidMolecular weight:197.21 kDaDilpacimab
CAS:Dilpacimab (ABT165) is a dual-variable antibody that targets DLL4 and VEGF pathways, showing potential in cancer research by blocking angiogenesis and Notch.Purity:95% - 97.7% (SDS-PAGE); 95.6% (SEC-HPLC)Color and Shape:LiquidAnbenitamab
CAS:Anbenitamab (KN-026) is a bispecific HER2 antibody for metastatic breast cancer research, blocking HER2 pathways and mediating ADCC.Color and Shape:LiquidPonezumab
CAS:Ponezumab (PF-04360365), a humanized IgG2 antibody, lowers Aβ in the CNS & boosts mice memory. Used in Alzheimer's research.Color and Shape:LiquidFidasimtamab
CAS:Fidasimtamab, a recombinant human IgG1 bispecific antibody, targets both HER2 and PD-1, bridging T cells and tumor cells to modulate immune responses.Purity:95% - 98.0% (SDS-PAGE); 98.3% (SEC-HPLC)Color and Shape:LiquidMolecular weight:144.72 kDaFaricimab
CAS:Faricimab,Bispecific antibody targeting Ang-2/VEGF-A. Prevents retinal I/R injury. Improves vision in w-AMD, DME, RVO.Purity:>95% (SDS-PAGE); >95% (SEC-HPLC) - >95% (SDS-PAGE); >95% (SEC-HPLC)Color and Shape:LiquidMolecular weight:146 kDaFutuximab
CAS:Futuximab is a chimeric monoclonal antibody targeting EGFR, commonly used in combination with zatuximab to form Sym004.Purity:95% - 97.5% (SDS-PAGE); 96.3% (SEC-HPLC)Color and Shape:LiquidMolecular weight:146.28 kDaIbrutinib-d5
CAS:Ibrutinib D5 is a deuterium-labeled Ibrutinib. Ibrutinib is an irreversible Btk inhibitor.Formula:C25H24N6O2Purity:98%Color and Shape:SolidMolecular weight:445.53Dasatinib-d8
CAS:Dasatinib D8 is deuterium-labeled dasatinib. Dasatinib is a dual Bcr-Abl and Src family tyrosine kinase inhibitor.Formula:C22H26ClN7O2SPurity:98%Color and Shape:SolidMolecular weight:496.06Apatinib-d8
CAS:Apatinib-d8 is a deuterated compound of Apatinib. Apatinib has a CAS number of 811803-05-1. Apatinib is an orally bioavailable and specific VEGFR2 inhibitor (IC50: 1 nM). In addition, this agent mildly inhibits c-Kit and c-SRC tyrosine kinases.Formula:C24H15D8N5OColor and Shape:SolidMolecular weight:405.52MAPK-IN-2
MAPK-IN-2 (compound 3h) is an efficacious MAPK inhibitor with antineoplastic properties that significantly hinders proliferation across various cancer cellFormula:C20H11Cl2N3OPurity:98%Color and Shape:SolidMolecular weight:380.23Dovitinib Dilactic Acid
CAS:Dovitinib dilactic acid: multitarget RTK inhibitor for FLT3/c-Kit (IC50=1-2 nM), FGFR1/3, VEGFR1-4 (IC50=8-13 nM), less effective on InsR, EGFR. Phase 4.Formula:C21H21FN6O·2C3H6O3Purity:98%Color and Shape:SolidMolecular weight:572.59ALK5-IN-79
CAS:ALK5-IN-79 (compound 57), an ALK inhibitor, exhibits anticancer activity by inhibiting the TGF-β1/SMAD signaling pathway. It effectively reduces the production of extracellular matrix (ECM) and collagen deposition. Moreover, ALK5-IN-79 demonstrates satisfactory pharmacokinetic (PK) properties and favorable in vivo tolerance.Formula:C23H27N7OColor and Shape:SolidMolecular weight:417.51ALKBH5-IN-3
CAS:ALKBH5-IN-3 (Compound 20m) is a selective ALKBH5 inhibitor (IC50=21 nM), effectively stabilizes ALKBH5 in HepG2 cells and elevates m6A levels in intact cells.Formula:C11H7F3N2O3Purity:98.32%Color and Shape:SolidMolecular weight:272.18ZM323881 hydrochloride
CAS:ZM323881 hydrochloride (ZM 323881 HCl) is a potent and selective VEGFR2 inhibitor.Formula:C22H19ClFN3O2Purity:99.43%Color and Shape:SolidMolecular weight:411.86Ref: TM-T1991
1mg34.00€5mg66.00€10mg96.00€25mg225.00€50mg369.00€100mg550.00€200mg780.00€1mL*10mM (DMSO)69.00€Erlotinib mesylate
CAS:Erlotinib: reversible inhibitor binding to ATP site of epidermal growth factor receptor.Formula:C23H27N3O7SPurity:98%Color and Shape:SolidMolecular weight:489.54(3S,4S)-Tofacitinib
CAS:(3S,4S)-Tofacitinib, a less active enantiomer of tofacitinib, is a Janus kinases inhibitor.Formula:C16H20N6OPurity:98%Color and Shape:SolidMolecular weight:312.37EGFR-IN-117
CAS:EGFR-IN-117 (Compound 8h) exhibits inhibitory activity against EGFR mutations, specifically targeting the tumor environment and inducing apoptosis in cancer cells. This compound effectively inhibits the proliferation of H1975, PC-9, and mutant EGFR cells including BaF3-EGFRL858R/T790M/C797S and BaF3–C797S/Del19/T790M, with IC50 values of 13 nM, 19 nM, 1.2 nM, and 1.3 nM respectively. Additionally, EGFR-IN-117 demonstrates anti-tumor activity in mouse models.Formula:C25H30BrN7O2SColor and Shape:SolidMolecular weight:572.52Icotinib
CAS:Icotinib (Conmana) is an orally available quinazoline-based inhibitor of epidermal growth factor receptor (EGFR), with potential antineoplastic activity.Formula:C22H21N3O4Purity:99.76% - 99.94%Color and Shape:SolidMolecular weight:391.42AD1058
CAS:AD1058 is a selective ATR inhibitor that crosses the blood-brain barrier with in vivo anticancer activity, used in the study of brain and CNS metastasis.Formula:C19H20N6O3SPurity:98.24%Color and Shape:SolidMolecular weight:412.47Ref: TM-T200105
1mg73.00€5mg160.00€10mg250.00€25mg537.00€50mg827.00€100mg1,108.00€200mg1,485.00€1mL*10mM (DMSO)170.00€EGFR-IN-109
CAS:EGFR-IN-109 (compound 4), an EGFR inhibitor, displays IC 50 values of 25.8 nM for EGFR WT and 182.3 nM for EGFR T790M. This compound halts the growth of cancer cells at the G2/M phase and triggers both early and late apoptosis. It is applicable in cancer research [1].Formula:C12H16N4OSColor and Shape:SolidMolecular weight:264.35HVH-2930
CAS:HVH-2930 is an inhibitor of Heat Shock Protein 90 (HSP90). It suppresses the cell viability of BT474 (Trastuzumab sensitive) and JIMT-1 (Trastuzumab resistant) by downregulating HSP90 client proteins such as HER2, p-HER2, AKT, p-AKT, cyclin D1, and survivin, with IC50 values of 6.86 μM and 4.42 μM, respectively. Additionally, HVH-2930 demonstrates antitumor efficacy in a mouse model and exhibits favorable pharmacokinetic properties in vivo.Formula:C29H36N4O3Color and Shape:SolidMolecular weight:488.62IGF-1R modulator 1
CAS:IGF-1Rmodulator 1 (Example 5) is an IGF-1R modulator featuring an EC50 of 0.29 μM (FGFR1), 0.25 μM (IGF1R), 0.34 μM (TrkA), and 0.39 μM (TrkB). This compound is useful in research on diseases characterized by impaired signaling of neurotrophic and/or other trophic factors, such as Alzheimer's disease.Formula:C22H17N3O4Color and Shape:SolidMolecular weight:387.39


